logo

For the Inventor, By the Inventor

Whitestone, NY, United States of America

Bernard F Erlanger

This inventor holds 15 USPTO granted patents. Top assignees: Columbia University, Lifecodes Corporation, National Distillers and Chemical Corporation. Active years: 1988-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernard F Erlanger. Retrieved from https://idiyas.com/inventor/bernard-f-erlanger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 93.3

Average Co-Inventor Count = 2.5

ph-index = 8

Forward Citations = 555(Granted Patents)


Company Filing History:

goldMedal14 out of 2,554 
 
Columbia University
 patents
silverMedal1 out of 12 
 
Lifecodes Corporation
 patents
bronzeMedal1 out of 321 
 
National Distillers and Chemical Corporation
 patents
4. 1 out of 124 
 
Quantum Chemical Corporation
 patents
where one patent can have more than one assignee

Years Active: 1988-2005

Loading Chart...
15 patents (USPTO):Explore Patents
1. 6946457 - Methods of treating sickle cell disease (2005-09-20),
2. 6593137 - Antibodies specific for fullerenes (2003-07-15),
3. 6287568 - Methods relating to immunogenic dextran-protein conjugates (2001-09-11),
4. 6177253 - Screening methods for the identification of anti-HIV compounds employing a cyclosporine-specific monoclonal antibody that cross-reacts with HIV-1 p24 (2001-01-23),
5. 5925532 - Enhancing the sensitivity of immunoassay procedures by use of antibodies (1999-07-20),
6. 5756301 - Endogenous taxol-like substance in human serum, monoclonal antibodies (1998-05-26),
7. 5650284 - Enhancing the sensitivity of immunoassay procedures by use of antibodies (1997-07-22),
8. 5604092 - Method for the detection of HIV-1 using a cyclosporine-specific (1997-02-18),
9. 5405785 - Derivatives of cyclosporine A, antibodies directed thereto and uses (1995-04-11),
10. 5350574 - Derivatives of cyclosporina A, antibodies directed thereto and uses (1994-09-27),
11. 5144010 - Method of producing monoclonal auto-anti-idiotypic antibodies (1992-09-01),
12. 4895955 - Non-radioactive carbodiimide precursor to nucleic acid probes (1990-01-23),
13. 4818684 - Auto-anti-idiotypic monoclonal antibodies to steroid receptors and uses (1989-04-04),
14. 4775745 - Diazonium compounds useful as components for nucleic acid probes (1988-10-04),
15. 4767704 - Protein-free culture medium (1988-08-30),

Title: The Innovations of Bernard F. Erlanger

Introduction

Bernard F. Erlanger is a notable inventor based in Whitestone, NY, with a remarkable portfolio of 15 patents. His work primarily focuses on medical advancements, particularly in the treatment of diseases and the development of specific antibodies.

Latest Patents

Erlanger's latest patents include innovative methods for treating sickle cell disease. This invention provides a method of treating a subject afflicted with sickle cell disease by administering an antiviral agent effective to inhibit sickling of a cell. Additionally, he has developed a method to inhibit the polymerization of hemoglobin, which involves contacting hemoglobin with an antiviral agent to prevent its polymerization. Another significant patent involves antibodies specific for fullerenes, where he created a hybridoma that produces a monoclonal antibody binding to fullerene C60. This invention also details the amino acid and encoding nucleic acid sequences of the heavy and light chains of the monoclonal antibody.

Career Highlights

Throughout his career, Erlanger has contributed to significant advancements in medical research. He has worked with prestigious institutions such as Columbia University and Lifecodes Corporation, where he has applied his expertise in developing innovative solutions to complex medical challenges.

Collaborations

Erlanger has collaborated with notable individuals in his field, including Bi-Xing Chen and William L. Cleveland. Their combined efforts have led to groundbreaking research and advancements in the medical field.

Conclusion

Bernard F. Erlanger's contributions to the field of medicine through his patents and collaborations highlight his dedication to innovation and improving healthcare solutions. His work continues to impact the lives of many, showcasing the importance of research and development in addressing critical health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…